Beacon Investment Advisory Services Inc. Purchases 198 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Beacon Investment Advisory Services Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,186 shares of the biopharmaceutical company’s stock after purchasing an additional 198 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.2% of Beacon Investment Advisory Services Inc.’s investment portfolio, making the stock its 28th largest holding. Beacon Investment Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $28,579,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after purchasing an additional 59,769 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after purchasing an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc grew its position in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on REGN shares. Citigroup started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective for the company. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ REGN opened at $750.22 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The stock’s fifty day moving average is $905.64 and its 200 day moving average is $1,019.64. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $82.44 billion, a P/E ratio of 18.57, a PEG ratio of 2.89 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.